A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma (Q33418737)

26 July 2017

title

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

belinostat

1 reference

ChEBI release 2020-05-28

Adam Lerner

0 references

Marie Beylot-Barry

0 references

Ranjana Advani

1 reference

26 July 2017

Ofer Shpilberg

1 reference

26 July 2017

Francine Foss

1 reference

26 July 2017

Madeleine Duvic

1 reference

26 July 2017

Kenneth B Hymes

1 reference

26 July 2017

Tanin Intragumtornchai

1 reference

26 July 2017

Arnuparp Lekhakula

1 reference

26 July 2017

Robert J Belt

1 reference

26 July 2017

Eric D Jacobsen

1 reference

26 July 2017

Guy Laurent

1 reference

26 July 2017

Dina Ben-Yehuda

1 reference

26 July 2017

Uwe Hillen

1 reference

26 July 2017

Poul Knoblauch

1 reference

26 July 2017

Gajanan Bhat

1 reference

26 July 2017

Shanta Chawla

1 reference

26 July 2017

Lee F Allen

1 reference

26 July 2017

Brad Pohlman

1 reference

26 July 2017

language of work or name

English

0 references

publication date

17 November 2014

1 reference

British Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

168

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

811-819

1 reference

Rational combinations using HDAC inhibitors

26 July 2017

cites work

1 reference

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.

21 January 2018

1 reference

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

21 January 2018

1 reference

Histone deacetylase inhibitors: current status and overview of recent clinical trials

21 January 2018

1 reference

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

Novel therapies in peripheral T-cell lymphomas

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

21 January 2018

1 reference

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

21 January 2018

1 reference

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

WHO-EORTC classification for cutaneous lymphomas

21 January 2018

1 reference

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13222

1 reference

26 July 2017

1 reference